Heptares Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
41
About the Report
About the Report
Summary
Heptares Therapeutics Ltd (Heptares) a subsidiary of Sosei Group Corp is a drug discovery company that develops small-molecule drugs. The company develops drugs for targeting G-protein-coupled receptors by utilizing its drug discovery technology platforms. Its technology platforms comprise StaR technology, StaR-driven X-ray crystallography, Biophysical Mapping and StaR fragment screening. Heptares' products are used in the treatment of Alzheimer's disease, schizophrenia, binge eating, type 2 diabetes, autism, depression, dyskinesia, migraine treatment, and others. The company partners with other pharma and biotech companies to develop its products. Heptares is headquartered in Welwyn Garden, the UK.
Heptares Therapeutics Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Heptares Therapeutics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Heptares Therapeutics Raises USD 21 Million In Series B Financing 12
Partnerships 13
Heptares Therapeutics Enters into Co-Development Agreement with DyNAbind 13
Heptares Therapeutics Enters into Research Agreement with Imperial College London 14
Heptares Therapeutics Enters into Research Agreement with Juntendo University 15
Heptares Therapeutics and PeptiDream Enter into Agreement 16
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 17
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 18
Jitsubo Enters into Agreement with Heptares Therapeutics 19
Heptares Therapeutics and leadXpro Enter into Agreement 20
Heptares Therapeutics to Form Partnership with Kymab 21
Heptares Therapeutics Enters into Agreement with Pfizer 22
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 23
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 24
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 25
Heptares Therapeutics Extends Collaboration with the UK Medical Research 26
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 27
Licensing Agreements 28
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 28
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 29
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 30
Acquisition 31
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 31
Sosei Acquires Heptares Therapeutics for USD400 Million 32
Heptares Therapeutics Ltd-Key Competitors 33
Heptares Therapeutics Ltd-Key Employees 34
Heptares Therapeutics Ltd-Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Government and Public Interest 36
Jan 04, 2018: Heptares Scientists Solve Structure of Complement C5a Receptor, an Important Drug Target for Inflammatory and Neurodegenerative Diseases, and Cancer 36
May 31, 2017: Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 37
Product News 38
May 31, 2017: Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 38
05/18/2017: Heptares to Receive USD 5 Million Milestone Payment from Teva 39
Clinical Trials 40
Apr 05, 2017: Heptares to Receive USD 12 Million Milestone Payment from Astrazeneca 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
List of Figure
List of Figures
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heptares Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Heptares Therapeutics Raises USD 21 Million In Series B Financing 12
Heptares Therapeutics Enters into Co-Development Agreement with DyNAbind 13
Heptares Therapeutics Enters into Research Agreement with Imperial College London 14
Heptares Therapeutics Enters into Research Agreement with Juntendo University 15
Heptares Therapeutics and PeptiDream Enter into Agreement 16
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 17
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 18
Jitsubo Enters into Agreement with Heptares Therapeutics 19
Heptares Therapeutics and leadXpro Enter into Agreement 20
Heptares Therapeutics to Form Partnership with Kymab 21
Heptares Therapeutics Enters into Agreement with Pfizer 22
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 23
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 24
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 25
Heptares Therapeutics Extends Collaboration with the UK Medical Research 26
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 27
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 28
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 29
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 30
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 31
Sosei Acquires Heptares Therapeutics for USD400 Million 32
Heptares Therapeutics Ltd, Key Competitors 33
Heptares Therapeutics Ltd, Key Employees 34
Heptares Therapeutics Ltd, Subsidiaries 35
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.